Long-acting injectable drugs to prevent and treat tuberculosis
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11133041
Developing long-lasting injectable TB medicines intended to prevent and treat tuberculosis, especially for people living with HIV.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11133041 on ClinicalTrials.gov |
What this research studies
Researchers are creating long-acting injectable formulations of next-generation diarylquinoline antibiotics that are highly active against Mycobacterium tuberculosis. They will formulate the drugs and test how long they persist and how effectively they kill TB bacteria in the lab and in validated animal models. This work builds on promising results where an injectable form of bedaquiline outperformed a standard regimen in mice, and the newer compounds (TBAJ-876 and TBAJ-587) are already in early human testing as oral drugs. The aim is to simplify preventive therapy and treatment so people — particularly those living with HIV — would not need months of daily pills.
Who could benefit from this research
Good fit: Ideal candidates would be people at high risk for TB or with latent TB infection who need preventive therapy, and patients with active TB, particularly those living with HIV.
Not a fit: People who cannot receive injectable medications, have known allergy to diarylquinolines, or need immediate, already-approved treatments may not receive direct benefit while this approach is still in development.
Why it matters
Potential benefit: If successful, these long-acting injections could replace months of daily TB pills, improving treatment completion and reducing TB deaths, especially among people with HIV.
How similar studies have performed: An injectable formulation of bedaquiline showed superior bactericidal activity in mouse models, but applying next-generation diarylquinolines as long-acting injections is promising yet still early-stage compared with standard TB treatments.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NUERMBERGER, ERIC L — JOHNS HOPKINS UNIVERSITY
- Study coordinator: NUERMBERGER, ERIC L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus